Q4 2024 MacroGenics Inc Earnings Call Transcript
Key Points
- Macrogenics Inc (MGNX) achieved significant clinical development milestones in 2024, positioning the company for continued progress in 2025.
- The company completed enrollment in the LORIKEET Phase 2 trial for lorigerlimab, targeting metastatic castration-resistant prostate cancer.
- Macrogenics Inc (MGNX) reported a substantial increase in total revenue for 2024, reaching $150 million, primarily due to milestones achieved under the Incyte License Agreement.
- The company has a promising ADC portfolio, with MGC026 and MGC028 in clinical development, and MGC030 in preclinical studies.
- Macrogenics Inc (MGNX) successfully completed the sale of MARGENZA to TerSera Therapeutics, providing non-dilutive capital to invest in their clinical pipeline and R&D efforts.
- The company reported a net loss of $67 million for the year ended December 31, 2024, compared to a net loss of $9.1 million in 2023.
- Research and development expenses increased to $177.2 million in 2024, driven by costs related to MGC028 and lorigerlimab.
- Selling, general, and administrative expenses rose to $71 million in 2024, partly due to an amendment fee paid to a former commercial partner.
- Macrogenics Inc (MGNX) decided not to pursue further internal development of vobra duo, exploring potential alternatives for partnering the program.
- The company's cash, cash equivalents, and marketable securities balance decreased to $201.7 million as of December 31, 2024, from $229.8 million in 2023.
Good afternoon. We will begin the MacroGenics fourth quarter and full-year 2024 corporate progress and financial results conference call in just a moment. All participants are in a listen-only mode. And we will conduct a question-and-answer session at the conclusion of the call.
At this point, I will turn the call over to Jim Karrels, Senior Vice President and Chief Financial Officer of MacroGenics. Please proceed.
Thank you, operator. Good afternoon, and welcome to MacroGenics conference call to discuss our fourth quarter and full-year 2024 financial and operational results. For anyone who has not had the chance to review the results, we've issued a press release this afternoon outlining today's announcements. This release is available under the Investors tab on our website at macrogenics.com. You may also listen to this conference call via webcast on our website, where it will be archived for 30 days, beginning approximately two hours after the call
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
